20 results
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
9 May 24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
6:58am
innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
7 May 24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
6:28am
on the website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
. European Union New Chemical Entity Exclusivity In the EU, innovative medicinal products approved on the basis of a complete and independent data package … to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Regulation FD Disclosure
8:30am
product launch
18 The right field team to launch an innovative rare disease medicine Mission-driven, patient-centric: bringing a novel therapy … indicated for WHIM syndrome Committed to Providing Innovative Solutions Dedicated support and education available through X4Connect and PANTHERx Rare
8-K
EX-99.1
1o2xuia bebf7afva
29 Apr 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
6:30am
8-K
EX-99.1
lr2slmug rn0kcnet
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.2
y2kg11
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
qobab5o
5 Aug 22
Regulation FD Disclosure
8:10am
8-K
EX-99.1
8weyha4
27 Nov 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants
5:18pm
8-K
EX-99.2
t6ensyw
27 Nov 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants
5:18pm
8-K
EX-99.1
m722shg9v
7 Nov 19
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
7:10am
8-K
EX-99.1
5edqgxwiv3inm l6
30 Sep 19
Subgroup exceeds target of 50% improvement in median progression-free survival
7:21am
8-K
EX-99.1
agzhfn
26 Jun 19
Other Events
8:44am
10-K
ea3 rahnaq5d
9 Mar 18
Annual report
12:00am
- Prev
- 1
- Next